Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Endra Life Sciences Inc. (NDRA:NASDAQ), powered by AI.
Endra Life Sciences Inc. is currently trading at $4.56. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Endra Life Sciences Inc. on Alpha Lenz.
Endra Life Sciences Inc.'s P/E ratio is -0.5.
“Endra Life Sciences Inc. trades at a P/E of -0.5 (undervalued) with modest ROE of -291.6%.”
Ask for details →Endra Life Sciences Inc. is a health technology company dedicated to developing meaningful innovations in the medical imaging sector. The company's primary focus is the advancement and commercialization of its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) platform, which aims to provide more effective imaging compared to traditional ultrasound. Endra seeks to improve early diagnosis and treatment monitoring by offering clinicians additional insights into liver fat quantification—an essential factor in detecting and managing non-alcoholic fatty liver disease (NAFLD). Operating in the global healthcare industry, Endra Life Sciences addresses significant diagnostic challenges by integrating cutting-edge technology into routine medical practices. The TAEUS platform stands out for its ability to enhance existing ultrasound systems, thereby facilitating cost-effective and non-invasive assessments of metabolic diseases. Endra Life Sciences plays a pivotal role in the ongoing shift towards more precise and accessible healthcare solutions. By bridging the gap between advanced imaging and everyday clinical use, the company contributes to the broader efforts of improving patient outcomes and reducing healthcare costs.
“Endra Life Sciences Inc. trades at a P/E of -0.5 (undervalued) with modest ROE of -291.6%.”
Ask for details →Endra Life Sciences Inc. (ticker: NDRA) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 21 employees. Market cap is $4M.
The current price is $4.56 with a P/E ratio of -0.51x and P/B of 1.59x.
ROE is -291.56%.